Frederick J Raal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6783950/publications.pdf

Version: 2024-02-01

213 papers	24,177 citations	23500 58 h-index	7496 151 g-index
224 all docs	224 docs citations	224 times ranked	14846 citing authors

#	Article	IF	Citations
1	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
2	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
3	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1489-1499.	13.9	1,838
4	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	13.9	1,352
5	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
6	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
7	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	6.3	813
8	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
9	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 2020, 382, 1507-1519.	13.9	758
10	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
11	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	6.3	615
12	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 341-350.	6.3	609
13	The Agenda for Familial Hypercholesterolemia. Circulation, 2015, 132, 2167-2192.	1.6	539
14	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473
15	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 382, 1520-1530.	13.9	463
16	Low-Density Lipoprotein Cholesterolâ€"Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia. Circulation, 2012, 126, 2408-2417.	1.6	456
17	Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 711-720.	13.9	413
18	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology,the, 2016, 4, 850-861.	5.5	329

#	Article	IF	Citations
19	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, 2014, 63, 1278-1288.	1.2	316
20	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	0.8	316
21	Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy. Circulation, 2011, 124, 2202-2207.	1.6	301
22	Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia. Circulation, 2013, 128, 2113-2120.	1.6	296
23	Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. Atherosclerosis, 2012, 223, 262-268.	0.4	285
24	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
25	Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation, 2014, 129, 234-243.	1.6	204
26	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes and Endocrinology,the, 2017, 5, 280-290.	5.5	191
27	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. Journal of Lipid Research, 2016, 57, 1086-1096.	2.0	180
28	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 689-699.	1.1	165
29	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.4	163
30	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160ÂÂmg/dl or Higher. Cardiovascular Drugs and Therapy, 2016, 30, 473-483.	1.3	160
31	Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015, 243, 257-259.	0.4	148
32	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	6.3	142
33	Long-term Low-Density Lipoprotein Cholesterolâ€“Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. JAMA Cardiology, 2017, 2, 598.	3.0	137
34	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes and Endocrinology,the, 2016, 4, 403-410.	5.5	133
35	Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, 277, 483-492.	0.4	128
36	Long-Term Evolocumab in Patients With FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 565-574.	1.2	126

#	Article	IF	Citations
37	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Journal of the American College of Cardiology, 2021, 77, 1182-1193.	1.2	122
38	Lipoprotein(a) in Homozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 522-528.	1.1	118
39	Effect of Alirocumab on Lipoprotein(a) Over â‰¥1.5ÂYears (from the Phase 3 ODYSSEY Program). American Journal of Cardiology, 2017, 119, 40-46.	0.7	116
40	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. European Heart Journal, 2014, 35, 2249-2259.	1.0	115
41	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	5.5	114
42	Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to Highâ€Dose Statin Therapy. Journal of the American Heart Association, 2013, 2, e000028.	1.6	109
43	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2019, 74, 2132-2146.	1.2	101
44	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	0.6	98
45	Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study. PLoS ONE, 2014, 9, e102830.	1.1	97
46	Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis, 1997, 135, 249-256.	0.4	94
47	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
48	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis, 2000, 150, 421-428.	0.4	85
49	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology, 2020, 17, 360-377.	6.1	82
50	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. European Heart Journal, 2018, 39, 1162-1168.	1.0	81
51	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis, 2008, 197, 400-406.	0.4	80
52	Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9. Annual Review of Medicine, 2014, 65, 417-431.	5.0	80
53	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 592-598.	1.1	77
54	Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. American Journal of Clinical Nutrition, 1994, 60, 579-585.	2.2	73

#	Article	IF	Citations
55	Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia. Circulation, 2020, 141, 1829-1831.	1.6	72
56	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
57	Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia. Journal of Pediatrics, 2010, 156, 231-236.e3.	0.9	66
58	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	0.8	60
59	A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infectious Diseases, 2011, 11, 244.	1.3	58
60	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
61	Pathogenesis of non-insulin-dependent diabetes mellitus in the black population of southern Africa. Lancet, The, 1992, 340, 460-462.	6.3	57
62	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). Journal of Atherosclerosis and Thrombosis, 2016, 23, 567-587.	0.9	52
63	Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. American Journal of Cardiology, 1999, 83, 1330-1333.	0.7	50
64	Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis, 2016, 248, 238-244.	0.4	50
65	Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis, 2003, 171, 273-279.	0.4	49
66	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 1448-1457.	0.6	48
67	From lipodystrophy syndromes to diabetes mellitus. Lancet, The, 2001, 357, 1379-1381.	6.3	47
68	The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. Postgraduate Medical Journal, 1993, 69, 552-556.	0.9	46
69	Recent Origin and Spread of a Common Lithuanian Mutation, G197del LDLR, Causing Familial Hypercholesterolemia: Positive Selection Is Not Always Necessary to Account for Disease Incidence among Ashkenazi Jews. American Journal of Human Genetics, 2001, 68, 1172-1188.	2.6	46
70	Pathogenesis and Management of the Dyslipidemia of the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2009, 7, 83-88.	0.5	44
71	Efficacy of Rosuvastatin in ChildrenÂWithÂHomozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. Journal of the American College of Cardiology, 2017, 70, 1162-1170.	1.2	42
72	Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature . International Journal of General Medicine, 2020, Volume 13, 121-129.	0.8	42

#	Article	IF	Citations
73	Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis, 2018, 277, 502-507.	0.4	37
74	Lomitapide and Mipomersenâ€"Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Current Atherosclerosis Reports, 2019, 21, 48.	2.0	36
75	New Therapies for Reducing Low-Density Lipoprotein Cholesterol. Endocrinology and Metabolism Clinics of North America, 2014, 43, 1007-1033.	1.2	35
76	Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 860-869.	0.6	35
77	Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease : cardiovascular topics. Cardiovascular Journal of Africa, 2012, 23, 389-395.	0.2	32
78	South African Dyslipidaemia Guideline Consensus Statement:. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, 155-165.	0.4	30
79	Cell adhesion molecules â€“ can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia?. Clinica Chimica Acta, 2000, 293, 105-113.	0.5	28
80	Lomitapide for homozygous familial hypercholesterolaemia. Lancet, The, 2013, 381, 7-8.	6.3	28
81	The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. European Journal of Preventive Cardiology, 2017, 24, 1843-1850.	0.8	28
82	Targeting LDL: Is lower better and is it safe?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 309-324.	2.2	27
83	Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1076-1081.	3.8	26
84	Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis, 1995, 115, 9-15.	0.4	26
85	Leptin, Adiponectin, and High-Sensitivity C-Reactive Protein in Relation to the Metabolic Syndrome in Urban South African Blacks With and Without Coronary Artery Disease. Metabolic Syndrome and Related Disorders, 2009, 7, 243-248.	0.5	26
86	Mipomersen preferentially reduces small low-density lipoprotein particle number inÂpatients with hypercholesterolemia. Journal of Clinical Lipidology, 2015, 9, 201-209.	0.6	26
87	Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. Clinical Drug Investigation, 1995, 10, 127-138.	1.1	25
88	Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. American Journal of Cardiology, 1999, 84, 1344-1346.	0.7	25
89	CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolemia among South African Indians. Clinical Genetics, 1997, 51, 394-398.	1.0	25
90	Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism. Circulation, 2013, 127, 2372-2374.	1.6	25

#	Article	IF	Citations
91	Consistent LDLâ€€ response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clinical Cardiology, 2018, 41, 1328-1335.	0.7	25
92	Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis, 2021, 320, 53-60.	0.4	25
93	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Current Cardiology Reports, 2015, 17, 104.	1.3	24
94	Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 101-108.	1.3	24
95	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. Journal of Clinical Lipidology, 2018, 12, 1199-1207.	0.6	24
96	Screening for diabetic retinopathy in South Africa with 60o retinal colour photography. Journal of Internal Medicine, 1996, 239, 43-47.	2.7	23
97	Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randleâ€™s cycle in its pathogenesis?. Clinical Endocrinology, 1997, 46, 365-368.	1.2	23
98	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650.	1.1	23
99	Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. Cardiovascular Journal of Africa, 2015, 26, 188-192.	0.2	23
100	Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Current Opinion in Lipidology, 2021, 32, 213-218.	1.2	22
101	Polygenic familial hypercholesterolaemia: does it matter?. Lancet, The, 2013, 381, 1255-1257.	6.3	21
102	Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Archives of Public Health, 2018, 76, 15.	1.0	21
103	Management of familial hypercholesterolemia in pregnancy. Current Opinion in Lipidology, 2021, 32, 370-377.	1.2	20
104	Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 111-119.	0.2	18
105	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis, 2021, 325, 46-56.	0.4	18
106	Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. Transplantation, 2002, 73, 587-590.	0.5	18
107	Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis, 1997, 129, 97-102.	0.4	17
108	The achievement of glycaemic, blood pressure and LDL cholesterol targets in patients with type 2 diabetes attending a South African tertiary hospital outpatient clinic. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2015, 20, 81-86.	0.4	17

#	Article	IF	Citations
109	Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2017, 22, 31-35.	0.4	17
110	A randomized clinical trial comparing metabolic parameters after 48 weeks of standardâ€•and lowâ€•dose stavudine therapy and tenofovir disoproxil fumarate therapy in <scp>HIV</scp>â€•infected <scp>S</scp>outh <scp>A</scp>frican patients. HIV Medicine, 2014, 15, 3-12.	1.0	16
111	CEPHEUS SA : a South African survey on the undertreatment of hypercholesterolaemia : cardiovascular topics. Cardiovascular Journal of Africa, 2011, 22, 234-240.	0.2	16
112	Prevalence of dyslipidaemia in statin-treated patients in South Africa : results of the DYSlipidaemia International Study (DYSIS). Cardiovascular Journal of Africa, 2013, 24, 330-338.	0.2	16
113	The relationship between the development and progression of microalbuminuria and arterial blood pressure in type 1 (insulin-dependent) diabetes mellitus. Diabetes Research and Clinical Practice, 1992, 16, 221-227.	1.1	15
114	A double mutant LDL receptor allele in a Cypriot family with heterozygous familial hypercholesterolemia. Human Genetics, 1997, 100, 101-103.	1.8	15
115	Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. Osteoporosis International, 1997, 7, 376-389.	1.3	15
116	Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. Journal of Internal Medicine, 1999, 246, 75-80.	2.7	15
117	High-Dose Statin Therapy Does Not Induce Insulin Resistance in Patients with Familial Hypercholesterolemia. Metabolic Syndrome and Related Disorders, 2012, 10, 351-357.	0.5	14
118	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. Journal of Diabetes Research, 2017, 2017, 1-6.	1.0	13
119	Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Current Opinion in Lipidology, 2018, 29, 72-79.	1.2	13
120	Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. BMC Medicine, 2021, 19, 30.	2.3	13
121	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiology, 2022, 18, 143-153.	0.5	13
122	Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial. Atherosclerosis, 2014, 235, e12.	0.4	12
123	Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis, 1994, 107, 213-219.	0.4	11
124	Autosomal recessive hypercholesterolaemia: Discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clinica Chimica Acta, 2007, 378, 33-37.	0.5	11
125	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovascular Drugs and Therapy, 2019, 33, 69-76.	1.3	11
126	Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. Aids, 2019, 33, 2049-2059.	1.0	11

#	Article	IF	Citations
127	Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis, 1995, 113, 289-292.	0.4	10
128	Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. Human Genetics, 1997, 101, 118-119.	1.8	10
129	Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutations. Molecular and Cellular Probes, 1998, 12, 149-152.	0.9	9
130	The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Medicine, 2013, 14, 217-225.	1.0	9
131	Quality of care delivered to type 2 diabetes mellitus patients in public and private sector facilities in Johannesburg, South Africa. International Journal of General Medicine, 2018, Volume 11, 383-390.	0.8	9
132	Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 andÂLDLRAP1 in African populations. PLoS ONE, 2020, 15, e0229098.	1.1	9
133	Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. Atherosclerosis Plus, 2021, 43, 3-6.	0.3	9
134	Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular Journal of Africa, 2019, 30, 15-23.	0.2	9
135	Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clinical Genetics, 1998, 54, 74-78.	1.0	8
136	Adiponectin and atherosclerosis risk factors in African hemodialysis patients: A population at low risk for atherosclerotic cardiovascular disease. Hemodialysis International, 2012, 16, 59-68.	0.4	8
137	The implementation of guidelines in a South African population with type 2 diabetes. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2013, 18, 154-158.	0.4	8
138	Multi-ethnic differences in HbA1c, blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes after a 4-year follow-up. International Journal of General Medicine, 2016, Volume 9, 419-426.	0.8	8
139	Evolocumab in patients with homozygous familial hypercholesterolemia in India. Journal of Clinical Lipidology, 2021, 15, 814-821.	0.6	8
140	The prevalence and incidence of and risk factors for, micro-albuminuria among urban Africans with type 1 diabetes in South Africa: An inter-ethnic study. International Journal of Diabetes Mellitus, 2010, 2, 148-153.	0.6	7
141	Low density lipoproteins and atherosclerosisâ€"quantity or quality?. Redox Report, 1995, 1, 171-176.	1.4	6
142	Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. Diabetes and Vascular Disease Research, 2010, 7, 151-157.	0.9	6
143	Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). Atherosclerosis, 2016, 252, e44.	0.4	6
144	Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovascular Disorders, 2019, 19, 61.	0.7	6

#	Article	IF	Citations
145	Never too old to benefit from lipid-lowering treatment. Lancet, The, 2020, 396, 1608-1609.	6.3	6
146	Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. American Journal of Preventive Cardiology, 2021, 7, 100224.	1.3	6
147	Novel therapies for familial hypercholesterolemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 188-195.	1.2	6
148	PCSK9 Inhibitors: From Natureâ€™s Lessons to Clinical Utility. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 840-854.	0.6	6
149	Insulin-Receptor Activity in Nondiabetic and Diabetic Urbanized South African Black Women. Diabetes Care, 1992, 15, 277-281.	4.3	5
150	Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemiaâ€”which is more important?. Clinica Chimica Acta, 2001, 314, 167-173.	0.5	5
151	Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. South African Medical Journal, 2022, 112, 426-432.	0.2	5
152	Relationship Between Plasma Insulin and Blood Pressure in South African Black Women in Johannesburg. Diabetes Care, 1992, 15, 556-558.	4.3	4
153	Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus. Lancet, The, 1994, 344, 1705.	6.3	4
154	Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. Human Mutation, 1998, 11, S232-S233.	1.1	4
155	The metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions among urbanised black South Africans with established coronary artery disease. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2007, 12, 6-12.	0.4	4
156	Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet, The, 2015, 385, 2124-2126.	6.3	4
157	Analysis of mutations causing familial hypercholesterolaemia in black South African patients of different ancestr. South African Medical Journal, 2017, 107, 145.	0.2	4
158	Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. Journal of Clinical Lipidology, 2021, 15, 379-380.	0.6	4
159	Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. Clinica Chimica Acta, 2021, 520, 71-75.	0.5	4
160	Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge. Cardiology and Therapy, 2022, 11, 1-7.	1.1	4
161	Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Journal of Clinical Lipidology, 2022, 16, 538-543.	0.6	4
162	Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. Clinica Chimica Acta, 1997, 258, 31-46.	0.5	3

#	Article	IF	Citations
163	Hypercholesterolemia in children and young adultsâ€"current management. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2009, 14, 9-12.	0.4	3
164	Case Studies: Unusual phaeochromocytomas in African families: the importance of genetic testing. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2010, 15, 92-94.	0.4	3
165	South African Dyslipidaemia Guideline Consensus Statement. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2013, 55, 9-18.	0.2	3
166	Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the 'Heart of Soweto' hospital registry study. BMJ Open, 2014, 4, e005069-e005069.	0.8	3
167	The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. Clinical Chemistry, 2016, 62, 1052-1053.	1.5	3
168	DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA VIA CASCADE SCREENING: THE WITS FIND-FH PROGRAM. Journal of the American College of Cardiology, 2018, 71, A1768.	1.2	3
169	Clinical, demographic and genetic characteristics of homozygous familial hypercholesterolemia patients worldwide: Interim results from the hofh international clinical collaborators (HICC) registry. Atherosclerosis, 2018, 275, e80.	0.4	3
170	6 MONTHLY INCLISIRAN AND ATHEROGENIC LIPOPROTEIN REDUCTIONS IN ORION-11. Journal of the American College of Cardiology, 2020, 75, 1853.	1.2	3
171	Cascade Screening for Familial Hypercholesterolemia in South Africa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2747-2755.	1.1	3
172	Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). European Heart Journal, 2020, 41, .	1.0	3
173	Acute Suppurative Thyroiditis Secondary to Escherichia coli Infection. European Journal of Case Reports in Internal Medicine, 2021, 8, 003009.	0.2	3
174	Circulating Endothelium-Related Adhesion Molecules in Black South African Patients with Graves' Disease. Endocrine, 2000, 12, 21-24.	2.2	2
175	The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2008, 13, 48-56.	0.4	2
176	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. Clinical Lipidology, 2013, 8, 243-256.	0.4	2
177	What matters most in pediatric familial hypercholesterolemia, genotype or phenotype?. Journal of Lipid Research, 2014, 55, 793-795.	2.0	2
178	Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome. Canadian Journal of Diabetes, 2014, 38, S18.	0.4	2
179	Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. Data in Brief, 2016, 7, 1458-1462.	0.5	2
180	Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 767-772.	0.6	2

#	Article	IF	Citations
181	LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL. Journal of the American College of Cardiology, 2019, 73, 1715.	1.2	2
182	Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2020, 25, 6-11.	0.4	2
183	Hyperpigmentation from Addisonâ€™s Disease. New England Journal of Medicine, 2021, 384, 1752-1752.	13.9	2
184	Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovascular Journal of Africa, 2019, 30, 279-284.	0.2	2
185	LIPID AND LIPOPROTEIN LEVELS IN HIV-INFECTED ADULTS WITH SEPSIS COMPARED TO HEALTHY HIV-INFECTED CONTROLS. African Journal of Infectious Diseases, 2020, 14, 1-9.	0.5	2
186	Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia. Frontiers in Pharmacology, 2022, 13, .	1.6	2
187	Basal Endocrine Status in African Dietary Iron Overload. Endocrine, 2003, 21, 241-244.	2.2	1
188	Postprandial Hyperglycemia in Urban South African Blacks with and without Coronary Artery Disease. Metabolic Syndrome and Related Disorders, 2009, 7, 23-29.	0.5	1
189	Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients. Journal of Clinical Lipidology, 2013, 7, 278.	0.6	1
190	CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIES. Canadian Journal of Cardiology, 2015, 31, S300-S301.	0.8	1
191	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. Journal of Clinical Lipidology, 2019, 13, 735-743.	0.6	1
192	More aggressive lipid lowering in people with diabetes?. Lancet Diabetes and Endocrinology,the, 2019, 7, 587-589.	5.5	1
193	Cryptogenic Cushing Syndrome Due to a White Lie. Clinical Chemistry, 2020, 66, 658-663.	1.5	1
194	An unusual presentation of insulinoma and the serious consequences of delayed diagnosis. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2020, 25, 28-30.	0.4	1
195	Homozygous familial hypercholesterolemia and its treatment by inclisiran. Expert Opinion on Orphan Drugs, 2020, 8, 197-208.	0.5	1
196	Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation. Frontiers in Cardiovascular Medicine, 2021, 8, 657719.	1.1	1
197	Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2022, 16, 356-357.	0.6	1
198	Statins: are they appropriate for all patients?. The Lancet Global Health, 2022, 10, e305-e306.	2.9	1

#	Article	IF	Citations
199	Corrigendum to â€œmicroalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia: Short communicationâ€. Atherosclerosis, 1995, 117, 147.	0.4	0
200	Dyslipidaemia in diabetesâ€”an approach to therapeutic intervention. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2006, 48, 42-47.	0.2	0
201	New-onset diabetes mellitus after renal transplantation. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2008, 13, 98-104.	0.4	0
202	Hypercholesterolaemia in children and young adultsâ€”current management. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2008, 50, 7-10.	0.2	0
203	Statin benefits in people with cardiovascular risk factors only. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2009, 14, 146-146.	0.4	0
204	The half-yellow man. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2015, 20, 140-141.	0.4	0
205	Pituitary apoplexy masquerading as meningitis. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2016, 21, 3-4.	0.4	0
206	A pain in the neck. BMJ, The, 2019, 367, l6008.	3.0	0
207	An unusual case of hypercholesterolaemia with liver dysfunction. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2020, 25, 31-35.	0.4	0
208	EVINACUMAB MARKEDLY REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADOLESCENT PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA. Journal of the American College of Cardiology, 2021, 77, 121.	1.2	0
209	Evinacumab markedly reduces low-density lipoprotein cholesterol in adolescent patients with homozygous familial hypercholesterolemia. Atherosclerosis, 2021, 331, e49-e50.	0.4	0
210	Effect of evolocumab on cognition in pediatric patients with familial hypercholesterolemia: Results from the HAUSER-RCT study. Atherosclerosis, 2021, 331, e258.	0.4	0
211	Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials. European Heart Journal, 2020, 41, .	1.0	0
212	Agranulocytosis as a Side-Effect of Carbimazole. Wits Journal of Clinical Medicine, 2022, 4, 61-63.	0.0	0
213	459â€ƒEvaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither. European Heart Journal Supplements, 2021, 23, .	0.0	0